Skip to content

Clinical trials

Observational Disease trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Disease Phase: Observational Country / region: United States Clear all

163 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20035
20041
20052
20062
20072
20086
200911
20103
20117
20126
20136
20143
20154
20164
20176
20186
20198
20206
202110
202210
202313
20245
202511
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed66
Recruiting40
Enrolling by invitation13
Active, not recruiting11
Unknown status11
Terminated10
Withdrawn8
Not yet recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Duke University5
Beckman Coulter, Inc.4
University of Minnesota4
National Institute of Allergy and Infectious Diseases (NIAID)3
National Institute of Neurological Disorders and Stroke (NINDS)3
Harbinger Health2
Johns Hopkins University2
Mayo Clinic2
National Cancer Institute (NCI)2
National Eye Institute (NEI)2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Disease163
Lung Neoplasms10
Prostatic Neoplasms10
Neoplasms9
Sepsis9
Alzheimer Disease7
Asthma6
Colorectal Neoplasms6
Emergencies6
Breast Neoplasms5

Trials

Showing 1 to 25 of 163. Each trial links to its page on Pharma Observatory.

63 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.